GENFIT 
By Press Release
Communiqué de Presse
GENFIT: CONVERSIONS INTO SHARES OF 25 BONDS OCA2012-2www . genfit . com
In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting held on December 18th,
2012and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested two conversions on January 7th and January 8th, 2013 for a total value of €250,000.
The first conversion of 10 bonds OCA2012-2 into 33,097 new shares was performed at a conversion rate of
€3.02, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (December 24th, 2012- January 4th, 2013) prior to the conversion request.
This second conversion of 15 bonds OCA2012-2 into 49,310 new shares was performed at a conversion rate of
€3.04, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (December 31th, 2012- January 7th, 2013) prior to the conversion request.
As a result of these two reserved share issues:
- The social capital of GENFIT has increased from €4,010,936.50 to €4,031,538.25;
- The number of shares representing the social capital of GENFIT has increased by 82,407, from
16,043,746 to 16,126,153 shares;
- The amount of the first installment of the bond loan agreement that remains to be converted is
€600,000.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.
GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates
at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in
Phase IIb.
Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially fr om those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.
[1]
Press Release
Communiqué de Presse
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Jean-François Mouney - CEO & Chairman of the Management Board
Ph. +333 2016 4000
Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 - barabian@milestones.fr
Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those an ticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.
[2]
|
distributed by
|
